临床外科杂志 ›› 2022, Vol. 30 ›› Issue (5): 429-432.doi: 10.3969/j.issn.1005-6483.2022.05.008

• 论著 • 上一篇    下一篇

局部进展期Siewert Ⅱ/Ⅲ型食管胃结合部腺癌新辅助化疗后腹腔镜手术及开放手术的临床对比分析

  

  1. 438200 湖北省浠水县人民医院胃肠外科(李栋梁);武汉大学人民医院东院胃肠外科(罗建飞)
  • 收稿日期:2021-08-21 接受日期:2021-08-21 出版日期:2022-05-20 发布日期:2022-06-20
  • 通讯作者: 罗建飞,Email:afei099@163.com

Clinical study of laparoscopic surgery and open surgery after neoadjuvant chemotherapy for locally advanced Siewert type Ⅱ/Ⅲ AEG

  1. Department of General Surgery,Xishui Peoples’ Hospital,Hubei,Xishui 438200, China
  • Received:2021-08-21 Accepted:2021-08-21 Online:2022-05-20 Published:2022-06-20

摘要:

[摘要] 目的 探讨局部进展期Siewert Ⅱ/Ⅲ型食管胃结合部腺癌(AEG)新辅助化疗后行腹腔镜全胃切除(LATG)+D2 淋巴结清扫术及开放全胃切除(OTG)+D2 淋巴结清扫术的疗效及安全性。方法 2015年1月~2019年12月浠水县人民医院局部进展期Siewert Ⅱ/Ⅲ型AEG病人46例,接受新辅助化疗后被随机分为LATG+D2淋巴结清扫术组(LATG组,23例)和OTG+D2淋巴结清扫术组(OTG组,23例),对两组病人的围手术期临床疗效、手术后近远期并发症等进行比较分析。结果 两组病人均完成术前新辅助化疗,均未出现治疗中断情况。两组病人均达到R0切除并顺利完成手术。LATG组与OTG组手术时间分别为(251.53±32.35)分钟和 (233.68±24.13)分钟,术中出血量分别为(146.00±47.68)ml和(181.21±42.54)ml,术后排气时间分别为(2.89±0.56)天和(3.24±0.34)天,术后住院时间分别为(12.65±2.17)天和(14.59±3.58)天,两组比较差异有统计学意义(P>0.05),而淋巴结清扫数分别为(32.19±3.23)枚和(30.84±2.85)枚,两组比较差异无统计学意义(P>0.05)。两组术后伤口感染分别为1例和4例,两组比较差异有统计学意义(P<0.05),吻合口狭窄分别为2例和2例,两组比较差异无统计学意义(P>0.05)。两组均无吻合口漏、吻合口出血、围手术期死亡等并发症。结论 局部进展期Siewert Ⅱ/Ⅲ型AEG病人新辅助化疗后,LATG组在肿瘤根治性切除、淋巴结清扫数目及术后出血、吻合口漏等方面与OTG组相当,但在术中出血、术后肠道功能恢复、伤口感染、术后住院时间等方面有优势。

关键词: Siewert Ⅱ/Ⅲ型食管胃结合部腺癌, 新辅助化疗, 腹腔镜全胃切除术, 开放全胃切除术

Abstract: [Abstract] Objective To investigate the efficacy and safety of advanced Siewert type Ⅱ/Ⅲ AEG neoadjuvant chemotherapy for retroperitoneal laparoscopic surgery and open surgery.Methods From January 2015 to December 2019,46 patients with locally advanced Siewert Ⅱ/Ⅲ AEG in Xishui People’s Hospital received neoadjuvant chemotherapy,and they were randomly divided into laparoscopic total gastrectomy(LATG)+D2 lymphadenectomy(LATG group,23 cases) or open total gastrectomy(OTG)+D2 lymphadenectomy(OTG group,23 cases).Results Both groups of patients completed preoperative neoadjuvant chemotherapy,and there was no interruption of treatment.Both groups achieved R0 resection and successfully completed the operation.There were significant differences in operation time[(251.53±32.35)min VS (233.68±24.13)min],intraoperative blood loss[(146.00±47.68)ml VS (181.21±42.54)ml],postoperative exhaust time[(2.89±0.56)d vs (3.24±0.34)d] and postoperative hospital stay[(12.65±2.17)d vs (14.59±3.58)d] between LATG group and OTG group(P<0.05).There was no significant difference in the number of lymph node dissection(32.19±3.23 VS 30.84±2.85)(P>0.05).In terms of postoperative complications,there was significant difference in wound infection(1 case,VS,4 cases)(P<0.05),but there was no significant difference in anastomotic stenosis(2 cases,vs,2 cases)(P>0.05).There were no serious complications such as anastomotic leakage,anastomotic bleeding and perioperative death in both groups.Conclusion After neoadjuvant chemotherapy for locally advanced Siewert Ⅱ/Ⅲ AEG patients,LATG group is equivalent to OTG group in radical tumor resection,lymph node dissection,postoperative bleeding and anastomotic leakage,but it has obvious advantages in intraoperative bleeding,postoperative intestinal function recovery,wound infection and postoperative hospital stay.

Key words: Siewert Ⅱ/Ⅲ AEG, neoadjuvant chemotherapy, laparoscopic total gastrectomy, open total gastrectomy

[1] 金成龙 张建国. 乳腺癌新辅助化疗后前哨淋巴结活检的研究进展[J]. 临床外科杂志, 2022, 30(4): 386-389.
[2] 刘永斌 王成 刘延杰 刘芳 岳萌 吕菲 刘广杰 王贵英. 转钴胺1在结直肠癌及其肺转移组织中的表达及临床意义[J]. 临床外科杂志, 2022, 30(1): 54-57.
[3] 雷浩 杨文荣 李仲华. OCA2 基因核苷酸rs4778137多态性对三阴性乳腺癌新辅助化疗效果的影响研究[J]. 临床外科杂志, 2021, 29(9): 842-846.
[4] 朱跃坤 朴大勋. 左半结肠癌致肠梗阻治疗中的临床特点[J]. 临床外科杂志, 2021, 29(5): 418-420.
[5] 张永辉 张春 付芬芬 张冬洁 谢凌铎 褚福涛 禹雪 徐硕 解云涛. 乳腺癌新辅助化疗后原发灶临床完全缓解对腋淋巴结转阴的预测作用[J]. 临床外科杂志, 2021, 29(1): 83-86.
[6] 韩加刚, 王振军. 梗阻性左半结肠癌治疗新策略-支架扩张联合新辅助化疗[J]. 临床外科杂志, 2020, 28(5): 401-403.
[7] 关树斌, 谷志涛, 茅腾等. 胸腺肿瘤淋巴结转移研究进展[J]. 临床外科杂志, 2019, 27(7): 622-625.
[8] 郑浩, 张仁泉. 局部进展期食管癌新辅助治疗的研究现状[J]. 临床外科杂志, 2019, 27(7): 626-629.
[9] 范威, 吴新红. 乳腺癌新辅助化疗后手术时机的选择[J]. 临床外科杂志, 2019, 27(3): 183-186.
[10] 邓宏武 周征宇 万能斌等. TAC与TC新辅助化疗方案治疗局部晚期乳腺癌疗效比较 [J]. 临床外科杂志, 2012, 20(11): 770-772.
[11] 周宜勇. 食管癌患者炎症因子水平与新辅助化疗疗效的关系分析[J]. 临床外科杂志, 2011, 19(11): 763-763.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 李光焰;张安平;王祥峰;等. 直肠癌切除术后吻合口狭窄14例分析[J]. 临床外科杂志, 2016, 24(10): 772 .
[2] 肖国栋;刘国辉. 跗骨窦切口联合经皮置钉技术微创治疗跟骨骨折的临床疗效分析[J]. 临床外科杂志, 2016, 24(10): 783 .
[3] 杨钦;张再重;王烈. 空肠间置术在Siewert Ⅱ型食管胃结合部腺癌中的应用[J]. 临床外科杂志, 2016, 24(11): 816 .
[4] 应敏刚;杨春康. 腹腔镜胃癌根治术并发症的防治策略[J]. 临床外科杂志, 2016, 24(11): 819 .
[5] 石汉平. 胃癌围手术期营养治疗[J]. 临床外科杂志, 2016, 24(11): 821 .
[6] 林伟箭;洪雪辉;许淑镇;等. 吸引器在腹腔镜胃癌根治术中的应用体会[J]. 临床外科杂志, 2016, 24(11): 824 .
[7] 方军;余阳;许涛;等. 小野寺营养预后指数在胃癌患者预后评估中的价值[J]. 临床外科杂志, 2016, 24(11): 831 .
[8] 王维君;那光玮;何科基;等. 根治性淋巴结清扫联合脾切除在残胃癌手术中的临床意义探究[J]. 临床外科杂志, 2016, 24(11): 835 .
[9] 吴超;谢迪;汪全新;等. 胃癌肝转移的临床病理特征及危险因素分析[J]. 临床外科杂志, 2016, 24(11): 839 .
[10] 许州;陈谦学;李明昌;等. 胶质瘤中miR383与其靶向circ_001634相互调控机制及作用研究[J]. 临床外科杂志, 2016, 24(11): 844 .